Supernus to Present at the 2019 J.P. Morgan Healthcare Conference
December 21 2018 - 4:15PM
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases, today announced that
the Company's management will present an overview and Company
update as well as host investor meetings at the 37th Annual J.P.
Morgan Healthcare Conference.
Date: Wednesday, January 9, 2019Time: 10:30 a.m. PT (1:30 p.m.
ET)Place: Westin St. Francis Hotel, San Francisco, Calif.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
A live webcast of the presentation can be accessed by visiting
‘Events & Presentations’ in the Investor Relations Section on
the Company's website at www.supernus.com. An archived replay of
the webcast will be available for 60 days on the Company's website
after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company
focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases. The Company
currently markets Trokendi XR® (extended-release topiramate) for
the prophylaxis of migraine and the treatment of epilepsy, and
Oxtellar XR® (extended-release oxcarbazepine) for the treatment of
partial seizures. The Company is also developing several product
candidates to address large opportunities in the CNS market,
including SPN-810 for the treatment of Impulsive Aggression in ADHD
patients, SPN-812 for the treatment of ADHD and SPN-604 for the
treatment of bipolar disorder.
Contact:
Jack A. Khattar, President and CEOGregory S. Patrick, Vice
President and CFOSupernus Pharmaceuticals, Inc.301-838-2591
Or
Investor Contact:Peter VozzoWestwicke PartnersOffice: (443)
213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024